NASDAQ$ARVN
Arvinas Inc. · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Arvinas reported financial results for the third quarter ended September 30, 2020 and provided a corporate update.
Arvinas reported a net loss of $30.8 million for the third quarter of 2020, compared to a net loss of $17.7 million for the same period in 2019. Research and development expenses increased to $30.0 million, and general and administrative expenses were $9.3 million. Cash, cash equivalents, and marketable securities totaled $248.6 million as of September 30, 2020.
- First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial.
- Dose escalation for Phase 1/2 clinical trials of ARV-110 and ARV-471 continues; program updates planned for December 2020.
- Arvinas and Pfizer entered a collaboration and supply agreement; initiation of Phase 1b combination of ARV-471 and Ibrance® expected in the fourth quarter of 2020.
- Arvinas expects its cash, cash equivalents, and marketable securities will be sufficient to fund its planned operating expenses and capital expenditures into 2022.
Headline financials
Revenue & EPS history
Arvinas · Revenue · Quarterly
$7.6M
Revenue by segment
Arvinas · $7.6M total across 1 segment · Q3 2020
- Collaboration Revenue$7.6M—100.0%
Forward guidance
Arvinas anticipates several milestones in 2021, including initiating Phase 1b investigations of ARV-110, sharing interim data from the Phase 2 dose expansion trial of ARV-110, initiating a Phase 2 dose expansion of ARV-471, sharing data from the Phase 1b cohort expansion of ARV-471, and filing an IND application for ARV-766.
Tailwinds
- Initiate the first of potentially two Phase 1b investigations of ARV-110 in combination with standard of care agents for mCRPC in 2021.
- Share interim data from the Phase 2 dose expansion trial of ARV-110 in 2021.
- Initiate a Phase 2 dose expansion of ARV-471 in 2021.
- Share data from the Phase 1b cohort expansion of ARV-471 in combination with Ibrance® in the second half of 2021.
- File an investigational new drug (IND) application for ARV-766, an androgen receptor degrader, in the first half of 2021.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2020
-2.4%
Avg return
Earnings day
-2.1%
Avg return
5 days after
-1.6%
Avg return
30 days after
30%
9 / 30 earnings
Positive
+11.8%
Q1 2019
Best reaction
-24.8%
Q1 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.4% | -10.2% | -31.0% | |
| Q4 2025 | +5.2% | +4.7% | -7.4% | |
| Q3 2025 | +0.5% | +17.3% | +34.1% | |
| Q1 2025 | -24.8% | -27.8% | -25.2% | |
| Q4 2024 | -6.8% | -3.5% | -54.9% | |
| Q3 2024 | -3.9% | -2.5% | -2.8% | |
| Q2 2024 | -1.0% | -7.0% | -6.3% | |
| Q1 2024 | +0.3% | -2.5% | -14.1% | |
| Q4 2023 | -5.8% | -3.1% | -15.4% | |
| Q3 2023 | -2.5% | -11.5% | +93.1% | |
| Q2 2023 | +2.1% | +6.8% | +12.8% | |
| Q1 2023 | +4.9% | +3.0% | -1.2% | |
| Q4 2022 | -7.0% | -10.8% | -23.0% | |
| Q3 2022 | -4.0% | +17.9% | -12.5% | |
| Q2 2022 | +3.8% | +4.5% | -19.3% | |
| Q1 2022 | -16.4% | -22.6% | -19.0% | |
| Q4 2021 | -2.6% | -4.4% | -5.4% | |
| Q3 2021 | +4.9% | +1.2% | -18.8% | |
| Q2 2021 | -4.3% | -8.9% | -13.4% | |
| Q1 2021 | -4.0% | -9.1% | -1.7% | |
| Q4 2020 | -1.0% | -8.0% | -15.6% | |
| Q3 2020 | -3.6% | +4.3% | +18.6% | |
| Q2 2020 | -5.0% | -11.1% | -23.0% | |
| Q1 2020 | -0.9% | -6.0% | -17.7% | |
| Q4 2019 | -3.2% | -1.8% | +14.2% | |
| Q3 2019 | +3.3% | +17.6% | +79.4% | |
| Q2 2019 | -4.6% | -0.2% | -1.5% | |
| Q1 2019 | +11.8% | +11.1% | +0.8% | |
| Q4 2018 | -3.0% | -6.9% | +42.9% | |
| Q3 2018 | -0.1% | +7.3% | -13.6% | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro